Abstract
Introduction
Genitourinary medicine (GUM) and family planning (FP) clinics provide a significant portion of the sexual health care available within the UK's National Health Service (NHS). GUM is mainly concerned with sexually transmitted infections, including Chlamydia trachomatis. GUM clinics also provide contraceptive advice, especially emergency contraception (EC). FP clinics offer mainly contraception provision, including EC, but some clinics undertake screening for chlamydial infection. If left untreated C. trachomatis infection is associated with a range of adverse sequelae, including pelvic inflammatory disease. These infections are costly both in terms of the cost of human suffering and the cost of treatment for the NHS. 1 Early diagnosis and treatment minimises these costs. There were three methods of EC used in the UK at the time of the study: progestogen-only emergency contraception (POEC), combined hormonal emergency contraception (CHEC) Yuzpe method, and the copper-containing intrauterine device (IUD). 2 The boundary, which may once have existed between these services, is becoming less distinct with greater co-operation between the professionals who work within each service. 3 This co-operation has been nurtured by an appreciation of the overlapping needs of the clients who access these services. [4] [5] [6] [7] [8] 
Study objectives and design
The objectives of the present study were two-fold. (1) To evaluate how FP clinics in London had incorporated C. trachomatis screening and treatment, specifically prior to procedures such as coil fitting, and in offering opportunistic screening of service users or targeted testing of symptomatic women. (2) To gauge the extent GUM clinics in North Thames were offering EC. The study comprised two cross-sectional surveys.
Study participants and methods
In Autumn 2000, two regional surveys were conducted within London and the former North Thames regions (1) to review the provision of chlamydia screening within FP clinics located in the London region and (2) to evaluate the access to EC from GUM clinics in the former North Thames region. Both surveys were co-ordinated by the North Thames Regional Audit Group for GU/HIV Medicine and had the support and encouragement of medical staff at the Faculty of Family Planning and Reproductive Health Care (FFPRHC) of the Royal College of Obstetricians and Gynaecologists (RCOG).
Both surveys used self-completed questionnaires to collect information. The questionnaires used to survey provision of chlamydia screening within FP clinics in London were mailed to each of 28 consultants and senior community medical off icers (SCMOs) in FP with instructions that they answer questions on behalf of clinics to reflect this provision. Only those doctors whose clinics offered screening were asked to complete the remainder of the survey.
The questionnaires used to survey provision of EC within GUM clinics were mailed to the lead consultant, or consultant designated to participate in regional audit, in each of 33 GUM clinics in North Thames, with similar instructions to supply answers which reflected clinic practice. Only those doctors whose GUM clinics offered EC were asked to complete the remainder of the survey.
Results

Provision of C. trachomatis screening in FP clinics
Completed survey questionnaires were returned by 22 consultants or SCMOs, with one doctor returning two forms to reflect practice within the two FP areas under his jurisdiction (response rate: 23/29 = 79%). Data are presented in terms of FP areas. FP areas were used in preference to single FP clinics since there may be several FP clinics within one area, but all operate under the same lead doctor and clinical guidelines. Surveying each FP clinic would have resulted in the same lead doctor completing numerous forms with identical information. The numbers of clinics within each FP area were not requested, however the 29 FP areas covered the whole of London region.
Fifteen FP areas (15/23, 65%) offered screening for C. trachomatis and eight did not. One of the eight FP areas not offering screening had offered this service for a 1-year trial period (the respondent did not indicate the dates when this trial commenced or finished). However, none of the women offered screening during the trial period gave informed consent to testing. Testing was therefore not possible and the service was withdrawn.
The following results apply only to those FP areas offering C. trachomatis screening. Table 1 gives details of which women were offered such screening. No FP areas offered routine screening to all women attending their area FP clinics. A total of 12/15 FP areas used swabs to collect urethral and endocervical material or endocervical material alone for screening. Screening using nucleic acid amplification techniques (NAAT) were offered at four FP areas (27%), three using first-pass urine (FPU/early morning sample) and one using material collected by swab. Enzyme-linked immunoassay (EIA) was employed by clinics in 11 FP areas (73%).
Eleven FP areas (11/15, 73%) were funded to provide C. trachomatis screening as a routine service provision. The other four used other sources of funding (not specified). One FP area (1/15, 7%) offered chlamydial screening to male partners of women found to have C. trachomatis infection. All other FP areas referred such men to other agencies, usually the GUM service. Three FP areas (3/15, 20%) were funded to provide treatment for women; one of these was only funded to offer antibiotic prophylaxis (drug not stated) to women prior to fitting of an intrauterine device (IUD).
Provision of EC by GUM clinics
Completed questionnaires were returned by 25/33 GUM clinics returned, giving a 76% response rate. The results below use the number of responders as denominator.
FP and contraception services. Consultants in 19/25 clinics (76%) stated that their clinics offered FP services. Fourteen of these clinics (74%) offered the service within the routine GUM clinic, with l1 of these (79%) also offering specific appointment/walk-in FP clinics. Four clinics (4/19, 21%) offered FP in designated young people's clinics only.
All 25 GUM clinics surveyed offered some form of EC. All GUM clinics provided condoms to their clients. Table 2 shows which health care professionals offered the service. A total of 19/25 clinics (76%) offered more comprehensive FP services. Table 3 outlines the range of methods of EC offered.
IUD EC.
A total of 8/25 (32%) clinics offered this method. Of the eight clinics providing IUD EC, five clinics (63%) had written guidelines for providing IUD EC.
Progestogen-only method: Levonelle 2.
A total of 24/25 clinics offered POEC (96%). Eighteen clinics (75%) had guidelines, with one clinic in the process of drafting a guideline. Three clinics (3/24, 13%) obtained written consent prior to administration. Twenty clinics (83%) did not prescribe antiemetics with Levonelle 2, the other four prescribing them only for women who developed symptoms of nausea with Levonelle 2 or other progestogen-only contraception, or who were anxious about this. Domperidone 20 mg and prochlorperazine 5 mg were the anti-emetics of choice (one unit did not indicate which anti-emetic was prescribed).
Combined oestrogen and progestogen: Yuzpe method. A total of 12/25 clinic offered CHEC (48%). Nine clinics (9/12, 75%) had written guidelines. Seven clinics (7/12, 58%) routinely prescribed anti-emetics with the Yuzpe method, with four clinics prescribing sometimes, and one did not prescribe. Prochlorpererazine, domperidone, cyclizine and metoclopramide were the anti-emetics of choice prescribed.
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Discussion
The survey of provision of C. trachomatis screening in FP clinics in the London region shows that only two-thirds of FP clinic areas were offering such screening to their patients. EIA was the main screening method , in preference to the newer NAAT, although studies have shown demonstrable cost benefits of the latter. 9 Of those FP areas providing screening, most were funded to provide targeted screening only, for example, women being referred for termination of pregnancy (TOP). These policies will inevitably result in many asymptomatic infections remaining undiagnosed and untreated. There is evidence that many clients referred to GUM clinics by FP clinics do not attend. 10, 11 It is of concern that only one-fifth of the FP clinic areas offering screening were also funded to offer treatment for C. trachomatis infection.
A major shortcoming of the present survey was that it did not request information about the number of clinics within each FP area or information about the numbers of women seen or local population size. Therefore, although results indicate that C. trachomatis testing was offered by 15/23 (65%) of FP areas surveyed, this might not reflect 65% of the population located within these FP areas, with actual screening coverage being lower or higher. This information is important in order to understand the future funding needs of FP services if they are to be able to offer screening for C. trachomatis
The survey of GUM clinics showed that all clinics were offering EC to clients and that three-quarters of clinics offered other FP service. Levonelle 2 was the most widely prescribed method, offered by all but one GUM clinic. Only one-half of GUM clinics surveyed prescribed the Yuzpe method, possibly reflecting the lower efficacy and greater risk of side effects of this method compared with Levonelle 2. 12 Only one-third of GUM clinics offer IUD EC, which may be due to a lack of time in consultations 13 or lack of expertise. Provision of EC was largely in accordance with the guidelines issued by the FFPRHC of the RCOG in use at the time of the survey. 2 This survey did not ask for information about the funding of EC provision in GUM clinics, although this information was requested in the survey of FP clinics regarding provision of C. trachomatis screening/treatment. This prevented comparison of the relative funding positions for these service provisions from being made.
Demonstrable health care benefits of offering a FP service within the GUM clinic have been published, 14, 15 illustrating the importance of offering contraception to women who do not access conventional sources of FP services. This contribution has, on occasion, been overlooked. 8, 16 The fairly high non-responder rates for both surveys perhaps reflect the limited time busy clinicians have to participate in surveys of this type. The non-responder rate for the GUM survey may perhaps be a reflection of 'survey fatigue', with units requested to participate in at least four surveys and audits per year, as part of the North Thames Regional Audit Programme. Given the increasing clinical governance work clinical specialties are obliged to undertake, including clinical audit, a similar effect might be attributable to the FP service. Nonetheless, these surveys provide some useful information regarding provision of 
